This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohn, J. N. Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB EPINEPHRINE HYDRALAZINE HYDROCHLORIDE ISOSORBIDE DINITRATE PRAZOSIN HYDROCHLORIDE Medline Plus Health Information Heart Failure Related Collections Cardio-renal physiology/pathophysiology

(Hypertension. 2001;37:346.)
© 2001 American Heart Association, Inc.

Novartis Award

Left Ventricle and Arteries

Structure, Function, Hormones, and Disease

Jay N. Cohn

From the Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis.

Correspondence to Jay N. Cohn, MD, Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN 55455. E-mail cohnx001{at}tc.umn.edu

The observation in the 1970s that the performance of the dysfunctional left ventricle was under the influence of aortic impedance led us to exploration of the role of the renin-angiotensin system and other hormonal systems in the progression of heart failure. The apparent efficacy of vasodilator drugs led to the first randomized, controlled trial in heart failure that demonstrated that all impedance-lowering drugs did not exert the same long-term benefit. Differences on the structural remodeling process in the myocardium and arterial vasculature were shown to account for the differential long-term response. We now recognize that the remodeling process in the left ventricle may be inhibited by nitrates, converting enzyme inhibitors, and ß-blockers, and this growth process leads to adverse outcomes. The impedance load on the left ventricle is influenced by vascular remodeling that also may be inhibited by drugs such as converting enzyme inhibitors. Thus, progression of cardiovascular disease is largely a consequence of structural changes that are hormonally mediated and may be inhibited by drug therapy.

Key Words: myocardium • arteries • angiotensin-converting enzyme inhibitors • heart failure

This article has been cited by other articles:

				D. A. Duprez Is the Female Heart More Sensitive to Aldosterone for Early Remodeling? Hypertension, May 1, 2004; 43(5): 936 - 937. [Full Text] [PDF]

				K. Meersschaert, L. Brun, M. Gourdin, S. Mouren, M. Bertrand, B. Riou, and P. Coriat Terlipressin-Ephedrine Versus Ephedrine to Treat Hypotension at the Induction of Anesthesia in Patients Chronically Treated with Angiotensin Converting-Enzyme Inhibitors: A Prospective, Randomized, Double-Blinded, Crossover Study Anesth. Analg., April 1, 2002; 94(4): 835 - 840. [Abstract] [Full Text] [PDF]